Cell Signaling & Oncology
The signaling pathways controlling cell growth and differentiation are almost invariably altered in cancer. During the course of tumor progression, cancer cells acquire a number of characteristic alterations. These include the capacities to proliferate independently of exogenous growth-promoting or growth-inhibitory signals, to invade surrounding tissues and metastasize to distant sites, to elicit an angiogenic response, and to evade mechanisms that limit cell proliferation, such as apoptosis and replicative senescence. These properties reflect alterations in the cellular signaling pathways that in normal cells control cell proliferation, motility, and survival. These interconnected pathways are being deciphered, but understanding the alterations that lead to cancer and correcting them is a substantial challenge. Among the key pathways are those controlling cell proliferation, which coordinate a response to the cellular environment, with the mTOR kinase as a critical node. Tumour development is influenced by infections and inflammation, and the complex role of the nuclear factor-B transcription factors is being unravelled. Expansion of tumour cells depends on nutrient supply and vascularization, which is orchestrated by the transcription factor known as HIF. And the metastatic spread of primary tumours to other organs is facilitated by many signaling pathways[1],[2].
Cell Signaling and Oncology products Library
For your convenience, you can order a library of all of our Cell Signaling and Oncology research related products. Make your personal library by cherry picking products of your interest from our comprehensive list (>800 products), or order all together not to miss any. The libraries will be shipped as 10 mM solutions (in DMSO, 250 µL of each selected Axon Ligand™) on a 96-well microtiter plate with a clear map of its contents.
Simply download our comprehensive list of epigenetics products below (Microsoft Excel (.xls)), check the products to be included, and return your list to order the library of your preference.
 Axon 5051 - Cell signaling and Oncology Library.xls |
|
[1] A. Eccleston, R. Dhand. Signalling in cancer. Nature 441, 423, editorial note
[2] G.S. Martin. Cell signaling and cancer. Cancer Cell. 2003 Sep;4(3):167-74.
| Axon ID | Name | Description | From price | |
|---|---|---|---|---|
| 1810 | Bortezomib | Inhibitor of 26S proteasome | €80.00 | |
| 4218 | Carfilzomib | Irreversible proteasome inhibitor | Inquire | |
| 2935 | COH000 | First-in-class, highly specific, covalent allosteric inhibitor of SUMO E1 | €175.00 | |
| 3709 | DKM 2-93 | Selective inhibitor of UBA5 | €70.00 | |
| 1798 | Eeyarestatin I | Inhibitor of endoplasmic reticulum associated protein degradation (ERAD) | €80.00 | |
| 3732 | HBX 41,108 | Inhibitor of deubiquitinase USP7 | €90.00 | |
| 3426 | IU1-47 | Potent and selective inhibitor deubiquitinase USP14 | €80.00 | |
| 3770 | KSQ-2479 | An allosteric, first-in-class USP1 (Ubiquitin Specific Protease 1) inhibitor | Inquire | |
| 2449 | LDN 57444 | Reversible, competitive inhibitor of UCH-L1 deubiquitinase | €95.00 | |
| 3724 | M-3258 | Selective inhibitor of LMP7 subunit of the immunoproteasome | Inquire | |
| 1869 | MG 132 | Inhibitor of 26S proteasome | €80.00 | |
| 2309 | ML 323 | Selective, reversible and potent inhibitor of the USP1–UAF1 deubiquitinase complex | €95.00 | |
| 2995 | ML 367 | Inhibitor of ATAD5 stabilization | €125.00 | |
| 3109 | ML-792 | Potent and selective inhibitor of SUMO-activating enzyme (SAE) | €145.00 | |
| 2678 | ML364 | Inhibitor of the deubiquitinase USP2 | €125.00 | |
| 2556 | MLN2238 | Selective and reversible 20S proteasome inhibitor | €85.00 | |
| 3829 | MLN7243 | Cell permeable small molecule inhibitor targeting ubiquitin-activating enzymes (UAE, also known as E1 enzymes) | Inquire | |
| 2557 | MLN9708 | Citrate prodrug of MLN2238, selective and reversible 20S proteasome inhibitor | €95.00 | |
| 2565 | N106 | Activator of E1 ligase mediated SERCA2a SUMOylation | €95.00 | |
| 2228 | NSC 687852 | Inhibitor of 19S regulatory-particle–associated deubiquitinases (DUBs: UCHL5 and USP14) | €90.00 | |
| 2199 | ONX 0914 | Selective inhibitor of LMP7 subunit of the immunoproteasome. | €70.00 | |
| 3849 | Oprozomib | Orally active and irreversible inhibitor of 20S proteasome | Inquire | |
| 2011 | P 005091 | Inhibitor of deubiquitinase USP7 and USP47 | €95.00 | |
| 1906 | P 22077 | Inhibitor of deubiquitinase USP7 and USP47 | €95.00 | |
| 1953 | PRT 4165 | E3 Ubiquitin ligase Bmi1/Ring1A inhibitor | €70.00 | |
| 3210 | RA375 | Potent RPN13 inhibitor | €180.00 | |
| 1904 | SMER 3 | Inhibitor of an SCF family E3 Ubiquitin ligase | €90.00 | |
| 2512 | Spautin 1 | Inhibitor of USP10 and USP13 and Beclin1 related autophagy | €95.00 | |
| 3608 | STD1T | Inhibitor of the deubiquitinase USP2a | €160.00 | |
| 3797 | TAK-981 oxalate | Inhibitor of SUMOylation | €110.00 | |